Oakland, New Jersey–based Collagen Matrix develops regenerative medicine and manufactures collagen- and mineral-based medical devices.
Scannell, a veteran of 30 years in leadership positions, joins the company after serving as president and COO of Stryker, a position he retired from in August 2021. Stryker said at the time that Scannell would officially transition from the role on Oct. 1, 2021, and act as an advisor to Stryker CEO Kevin Lobo until his official retirement date set for March 31, 2023.
During the earlier stages of his career, Scannell led Stryker’s neurotechnology, spine and medsurg business and served as GM of the company’s biotech division. He also serves as the chair of Insulet’s board of directors and is on the board of directors for Novocure.
“Tim’s appointment represents a meaningful addition to our board, and I look forward to the strength and experience he will bring to the table,” Collagen Matrix President and CEO Shawn McCarthy said in the news release. “He joins Collagen Matrix at an exciting time as we continue to accelerate our growth strategy and further our vision of improving patient lives through innovative regenerative devices. We are confident that Tim’s diversified leadership experience and proven track record will provide valuable perspective.”
